On July 31st, Golonghui reported that Oppenheimer raised its target price for Nasdaq from $75 to $78 and maintained its "outperform" rating.
奥本海默上调纳斯达克目标价至78美元
Jefferies raised the Nasdaq target price of Alzheimer's to $ 78.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.